ATE406155T1 - Triptolid-prodrugs zur krebstherapie - Google Patents
Triptolid-prodrugs zur krebstherapieInfo
- Publication number
- ATE406155T1 ATE406155T1 AT02704187T AT02704187T ATE406155T1 AT E406155 T1 ATE406155 T1 AT E406155T1 AT 02704187 T AT02704187 T AT 02704187T AT 02704187 T AT02704187 T AT 02704187T AT E406155 T1 ATE406155 T1 AT E406155T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer therapy
- triptolide prodrugs
- prodrugs
- triptolide
- irinotecan
- Prior art date
Links
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 title abstract 2
- 238000011275 oncology therapy Methods 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/766,156 US6620843B2 (en) | 2001-01-19 | 2001-01-19 | Anticancer treatment using triptolide prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406155T1 true ATE406155T1 (de) | 2008-09-15 |
Family
ID=25075572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02704187T ATE406155T1 (de) | 2001-01-19 | 2002-01-18 | Triptolid-prodrugs zur krebstherapie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620843B2 (de) |
| EP (1) | EP1359909B1 (de) |
| JP (1) | JP2004517882A (de) |
| AT (1) | ATE406155T1 (de) |
| AU (1) | AU2002237884B2 (de) |
| CA (1) | CA2435322A1 (de) |
| DE (1) | DE60228544D1 (de) |
| WO (1) | WO2002056835A2 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4680589B2 (ja) | 2002-05-31 | 2011-05-11 | ファーマジェネシス， インコーポレイテッド | アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体 |
| CN100398544C (zh) * | 2002-09-18 | 2008-07-02 | 成都达远药物有限公司 | 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用 |
| WO2004058246A1 (en) * | 2002-12-17 | 2004-07-15 | Pharmagenesis, Inc. | Triptolide derivatives as immunomodulator and anticancer agents |
| US6943259B2 (en) * | 2003-02-25 | 2005-09-13 | Pharmagenesis, Inc. | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
| US7820834B2 (en) * | 2003-12-24 | 2010-10-26 | Pharmagenesis, Inc. | Triptolide 5,6-derivatives as immunomodulators and anticancer agents |
| CN1917893A (zh) * | 2004-02-09 | 2007-02-21 | 美国泛华医药公司 | 从雷公藤多苷中分离雷公藤内酯醇化合物的方法 |
| DK1732536T3 (da) * | 2004-03-02 | 2012-06-25 | Pharmagenesis Inc | Tripolidlactonringderivater som immunomodulatorer og anticancermidler |
| WO2006012204A2 (en) * | 2004-06-25 | 2006-02-02 | Pharmagenesis, Inc. | Method for treatment of inflammatory disorders using triptolide compounds |
| US8617906B2 (en) | 2004-10-13 | 2013-12-31 | Pharmagenesis, Inc. | Identification and screening of triptolide target molecules |
| EP1946758A1 (de) * | 2007-01-18 | 2008-07-23 | Pierre Fabre Medicament | Behandlung akuter myeloischer Leukämie |
| WO2010030763A2 (en) * | 2008-09-10 | 2010-03-18 | Bind Biosciences, Inc. | High throughput fabrication of nanoparticles |
| CN104387406A (zh) | 2009-02-05 | 2015-03-04 | 药物起源公司 | 作为抗癌药和免疫调制剂的雷公藤内酯 c-环衍生物 |
| US9150600B2 (en) | 2009-05-07 | 2015-10-06 | Regents Of The University Of Minnesota | Triptolide prodrugs |
| EP2427467B1 (de) * | 2009-05-07 | 2015-08-05 | Regents of the University of Minnesota | Triptolid-prodrugs |
| US20130195896A1 (en) * | 2010-04-07 | 2013-08-01 | Steward Research And Specialty Projects Corporation | Compositions and methods for the treatment of a neoplasia |
| US9846160B2 (en) | 2012-02-27 | 2017-12-19 | Board Of Regents, The University Of Texas Systems | Ganglioside GD2 as a marker and target on cancer stem cells |
| CN108601952B (zh) * | 2016-02-04 | 2022-03-04 | 约翰霍普金斯大学 | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 |
| CN107698653B (zh) * | 2017-10-11 | 2019-08-27 | 中国农业科学院蜜蜂研究所 | 一种雷公藤甲素半抗原及其制备方法与应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005108A (en) | 1973-04-03 | 1977-01-25 | Research Corporation | Novel anti-leukemic diterpenoid triepoxides |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| US5663335A (en) * | 1996-03-01 | 1997-09-02 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| US5962516A (en) | 1997-02-28 | 1999-10-05 | Pharmagenesis, Inc. | Immunosuppressive compounds and methods |
| US6548537B1 (en) * | 1998-09-02 | 2003-04-15 | Pharmagenesis, Inc. | Triptolide prodrugs having high aqueous solubility |
| DE69932649T2 (de) * | 1998-09-02 | 2007-08-09 | Pharmagenesis, Inc., Palo Alto | Triptolid-Prodrugs mit hoher Wasserlöslichkeit |
| US6294546B1 (en) * | 1999-08-30 | 2001-09-25 | The Broad Of Trustees Of The Leland Stanford Junior University | Uses of diterpenoid triepoxides as an anti-proliferative agent |
| US6569893B2 (en) * | 2001-03-15 | 2003-05-27 | Pharmagenesis, Inc. | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents |
-
2001
- 2001-01-19 US US09/766,156 patent/US6620843B2/en not_active Expired - Fee Related
-
2002
- 2002-01-18 AU AU2002237884A patent/AU2002237884B2/en not_active Ceased
- 2002-01-18 DE DE60228544T patent/DE60228544D1/de not_active Expired - Fee Related
- 2002-01-18 AT AT02704187T patent/ATE406155T1/de not_active IP Right Cessation
- 2002-01-18 EP EP02704187A patent/EP1359909B1/de not_active Expired - Lifetime
- 2002-01-18 WO PCT/US2002/001650 patent/WO2002056835A2/en not_active Ceased
- 2002-01-18 JP JP2002557346A patent/JP2004517882A/ja active Pending
- 2002-01-18 CA CA002435322A patent/CA2435322A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002056835A3 (en) | 2003-02-27 |
| AU2002237884B2 (en) | 2006-08-17 |
| EP1359909A4 (de) | 2005-03-09 |
| DE60228544D1 (de) | 2008-10-09 |
| WO2002056835A2 (en) | 2002-07-25 |
| CA2435322A1 (en) | 2002-07-25 |
| JP2004517882A (ja) | 2004-06-17 |
| EP1359909A2 (de) | 2003-11-12 |
| US6620843B2 (en) | 2003-09-16 |
| US20020099051A1 (en) | 2002-07-25 |
| EP1359909B1 (de) | 2008-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60228544D1 (de) | Triptolid-prodrugs zur krebstherapie | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| SG160412A1 (en) | Anti-igfr1 antibody therapeutic combinations | |
| TW200612918A (en) | Lonidamine analogs | |
| PT1242060E (pt) | Tratamento da doenca metastatica | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| MXPA05012421A (es) | Tratamiento sinergistico de cancer usando inmunomeros junto con agentes quimioterapeuticos. | |
| DK1556058T3 (da) | Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi | |
| HUP0400231A3 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
| IL146125A0 (en) | Novel quinones as disease therapies | |
| WO2002102306A3 (en) | Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy | |
| TNSN07294A1 (en) | Treatment of metastasized tumors | |
| EA200200808A1 (ru) | Модифицированные цитокины, предназначенные для применения в терапии рака | |
| MX2009010269A (es) | Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana. | |
| EP1635764A4 (de) | Konjugat für spezifisches targeting von anti-krebsmitteln gegen krebszellen und seine herstellung | |
| PL369148A1 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
| HUP0302913A3 (en) | Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same | |
| MX2007004596A (es) | Nitrobenzoindoles y su uso en terapia del cancer. | |
| AR024907A1 (es) | Uso de inhibidores de la produccion y/o accion de la il-18 y composiciones farmaceuticas formuladas con dichos inhibidores para el tratamiento demetastasis de tumores. | |
| WO2005123908A3 (en) | Novel cancer cell lines and uses thereof | |
| MXPA05008902A (es) | Soluciones de drogas en mentol. | |
| IL178939A (en) | Double and triple combinations suitable for synergistic treatment of breast cancer, including pharmaceuticals and their use in the manufacture of drugs and drugs for the treatment of breast cancer | |
| MXPA02012911A (es) | Compuestos de rutenio (ii) para el uso en terapia del cancer. | |
| TW200504051A (en) | Novel acridine derivatives and their use as medicaments | |
| WO2004026846A8 (en) | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |